Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

April 10, 2021

Study Completion Date

April 10, 2021

Conditions
Healthy Volunteer Study
Interventions
DRUG

Period 1: AT-527 550 mg

AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1

DRUG

Period 2: carbamazepine

Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25

DRUG

Period 3: AT-527 550 mg + carbamazepine

AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26

DRUG

Period 3: AT-527 1100 mg + carbamazepine

AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26

Trial Locations (1)

Unknown

Atea Study Site, Montreal

Sponsors
All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Atea Pharmaceuticals, Inc.

INDUSTRY